The European Brain Council will host an online event on the subject of 'Best practices for patient safety: An EU-wide view on the use of medicines off-label' on 30 November at 14:30 (CET).

The European Academy of Neurology and the European Alzheimer's Disease Consortium hold a joint session on Wednesday, 1 December, 2021.

Free EAN-BRAINS workshop taking place on 9-11 December.

Alzheimer Europe has published a new edition of its Dementia in Europe policy magazine, in an electronic format.

EAN has endorsed the ESRS's Sleep Medicine Texbook (2nd ed.) which is available to EAN members at the ESRS member price.

Read the latest reports on EAN clinical fellowships in London (UK) and Antwerp (BE)

Read the latest reports on EAN clinical fellowships in Unna (DE) and Graz (AT)!

Follow-up interview with Dr. Tsuyoshi Hamaguchi from the Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Japan.

Congratulations to the winners of this year’s Investigator Award! Each winner receives free registration for the 8th EAN Congress in Vienna and an award certificate.

On 2 October, 2021, the Council of Delegates of the World Federation of Neurology elected Prof. Wolfgang Grisold to be their next president.

This study aimed to describe gross and microscopic CNS pathology findings from the autopsies and correlate them with the clinical and laboratory characteristics of 45 patients with COVID-19 from Manaus, Amazonas, Brazil.

This study quantifies changes in neuro-oncological care during the height of the pandemic and investigates patient outcomes in 2020 compared to a historical control.

In this article the authors aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache.

From a sample of 208 consecutive non-neurological patients hospitalised for COVID-19 disease, 165 survivors were re-assessed at 6 months according to a structured standardised clinical protocol.

The objective of this study was to estimate whether the risk of death from COVID-19 in patients with multiple sclerosis (MS) exceeds that of the general population.